Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.

Rich, P.;Bourcier, M.;Sofen, H.;Fakharzadeh, S.;Poulin, Y.;et.al.
(2014) British Journal of Dermatology — Vol. 170, n° 2, p. 398-407 (2014)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 318.07 KB
Request a copy

Details

Authors
Show more
Abstract
Most patients with psoriasis have nail changes, and treating nail psoriasis is challenging.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Rich, P., Bourcier, M., Sofen, H., Fakharzadeh, S., Wasfi, Y., Wang, Y., Kerkmann, U., Ghislain, P.-D., & Poulin, Y. (2014). Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. British Journal of Dermatology, 170(2), 398-407. https://doi.org/10.1111/bjd.12632 (Original work published 2014)